Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS15 | P98073 | 7/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15946453 | 0.95 | TMPRSS15 (0.44) | TMPRSS15PPARAITGB3ITGA2BSUCNR1 | |
| SCHEMBL14821500 | 0.92 | TMPRSS15 (0.43) | TMPRSS15PPARAITGB3ITGA2BPRSS1 | |
| SCHEMBL14821509 | 0.92 | TMPRSS15 (0.43) | TMPRSS15PPARAITGB3ITGA2BSUCNR1 | |
| SCHEMBL15948343 | 0.91 | PPARA (0.44) | TMPRSS15PPARAITGB3ITGA2B | |
| SCHEMBL14821124 | 0.88 | SMN1; SMN2 (0.46) | TMPRSS15ALDH1A1POLBL3MBTL1 | |
| SCHEMBL14821755 | 0.87 | ITGB3 (0.41) | TMPRSS15PPARAITGB3ITGA2BPRSS1 | |
| SCHEMBL14821496 | 0.87 | TMPRSS15 (0.44) | TMPRSS15PPARAITGB3ITGA2BPRSS1 | |
| SCHEMBL14821505 | 0.86 | TMPRSS15 (0.44) | TMPRSS15PPARAITGB3ITGA2BSUCNR1 | |
| SCHEMBL15946454 | 0.85 | TMPRSS15 (0.43) | TMPRSS15PPARA | |
| SCHEMBL14821511 | 0.84 | TMPRSS15 (0.43) | TMPRSS15PPARAITGB3ITGA2BPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758367-B1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | DoubleHill GmbH (DE) | 2015-11-18 | — | — | EP | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | IDH3A, IDH3B, IDH2 | TMPRSS15 1400/4885PPARA 3425/4885ITGB3 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.